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and	 percent	 within	 therapeutic	 range	 (1000–	4000  ng/ml)	 were	 examined,	 in	
addition	to	EFV	and	8OH-	EFV	concentration	differences	between	patients	expe-
riencing	adverse	effects.	CYP2B6	c.516T	allele	 frequency	was	53%.	Plasma	EFV	











WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
High	efavirenz	 (EFV)	concentrations	are	 strongly	associated	with	 the	develop-
ment	of	adverse	effects,	particularly	central	nervous	system	(CNS)	and	psychiatric	




active	 antiretroviral	 therapy	 used	 for	 the	 treatment	 of	
patients	infected	with	HIV.1	EFV	was	introduced	onto	the	
market	in	19982	and	has	been	recommended	by	the	World	
Health	Organization	as	 the	 first-	line	drug	 for	HIV	treat-
ment	for	more	than	20 years.3	Although	EFV	was	recently	
replaced	 by	 dolutegravir	 as	 the	 recommended	 first-	line	
drug,4	 it	 remains	 as	 an	 alternative	 first-	line	 regimen	 for	
adolescents	and	adults,	and	as	a	first-	line	therapy	in	a	few	
countries	in	Asia	and	the	Western	Pacific	regions.5
Despite	 its	 efficacy	 in	 the	 treatment	 of	 HIV,2,6	 EFV	
often	leads	to	the	development	of	adverse	effects,	in	par-
ticular	those	of	the	central	nervous	system	(CNS)	and	psy-
chiatric	 toxicities.7,8	 The	 likelihood	 of	 developing	 these	
adverse	effects	and	for	achieving	therapeutic	efficacy	has	











of	 plasma	 concentrations,	 drug-	related	 toxicity,	 and	
drug	 response.16	 This	 variability	 is	 multifactorial,	 and	
includes	 differences	 in	 metabolism,	 ethnicity,	 gender,	
body	 weight,	 drug	 compliance,	 use	 of	 comedications,	
presence	of	concomitant	diseases,	as	well	as	genetic	fac-
tors.17	Variations	 in	body	weight,	 ethnicity,	 and	comedi-
cation	affect	the	clearance	of	EFV18,19	yet	the	association	
between	gender	and	plasma	EFV	concentrations	appears	




Cytochrome	 P450	 CYP2B6	 is	 the	 main	 isoenzyme	
involved	 in	 hepatic	 EFV	 metabolism.	 About	 70%	 of	
EFV	 is	 metabolized	 to	 8-	hydroxy-	efavirenz	 (8OH-	EFV),	
predominantly	 by	 CYP2B6.22	 CYP2B6	 is	 also	 involved	








with	 the	 occurrence	 of	 adverse	 events	 and	 EFV	 discon-






Even	 though	 PNG	 shows	 the	 highest	 prevalence	 of	
the	 c.516T	 variant,	 there	 are	 no	 studies	 evaluating	 the	
relationship	among	plasma	EFV	concentrations,	adverse	






WHAT QUESTION DID THIS STUDY ADDRESS?
Whether	 there	 is	 a	gene-	dose	association	among	 the	c.516G>T	genotype,	EFV	
and	metabolite	concentrations,	and	adverse	events.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
In	 PNG,	 the	 CYP2B6	 c.516T/T	 genotype	 was	 strongly	 associated	 with	 sub-
stantially	 higher	 plasma	 EFV	 concentrations	 and	 lower	 metabolic	 ratio	
(8-	hydroxy-	efvairenz/efavirenz)	 in	 a	 gene-	dose	 manner.	 In	 PNG,	 plasma	 efa-
virenz	and	8-	hydroxy-	efavirenz	concentrations	were	not	significantly	higher	 in	
patients	experiencing	adverse	effects	after	the	first	3 months	of	treatment.










Patients and sample collection
One	 hundred	 fifty-	six	 patients	 receiving	 EFV	 combina-
tion	antiretroviral	therapy	at	the	HIV	Heduru	Clinic	(Port	








300  mg	 and	 lamivudine	 300  mg	 as	 a	 single	 tablet	 (dura-
tion	 of	 therapy	 ranged	 between	 3  months	 and	 13  years).	
Demographic	 data,	 such	 as	 age,	 body	 weight,	 gender,	








lithium	 heparin	 (LiHep)	 blood	 collection	 tubes	 (BD	
vacutainers,	 Melbourne,	 Australia).	 CAT	 tubes	 were	 al-
lowed	 to	 clot	 at	 room	 temperature	 then	 heat	 treated	 at	
60°C	for	1 h	and	stored	at	−20°C.	LiHep	tubes	were	also	
heat	 treated	 at	 60°C	 for	 1  h	 in	 a	 water	 bath,	 then	 cen-





EFV and 8OH- EFV plasma concentrations
Steady-	state	 EFV	 and	 8OH-	EFV	 plasma	 concentrations	
were	 determined	 using	 a	 Nexera	 ultra-	high-	performance	
liquid	chromatography	(UHPLC)	system	coupled	to	a	liquid	
chromatography	 mass	 spectrometry	 (LCMS)-	8040	 triple	
quadrupole	mass	spectrometer	(Shimadzu,	Tokyo,	Japan).34
Plasma	 (100	 µl)	 was	 added	 into	 a	 tube	 containing	 10	

























DNA extraction and genotyping
DNA	 was	 extracted	 from	 defrosted	 and	 vortexed	 CAT	
tube	 and	 LiHep	 buffy	 coat/red	 blood	 cell	 samples	 using	




DNA	 was	 quantified	 by	 Quanti-	IT	 dsDNA	 broad-	range	
assay	kit	(Thermo	Fisher,	Adelaide,	Australia)	according	
to	 the	 manufacturer’s	 instructions.	 For	 samples	 with	
low	DNA	yield	(<100 ng),	multiple	extractions	were	per-
formed,	 combined,	 and	 concentrated	 using	 ReliaPrep	
DNA	Clean-	up	and	Concentration	System	kits	according	
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EFV	and	8OH-	EFV	concentrations	and	MR,	calculated	as	
plasma	8OH-	EFV	concentration/EFV	concentration.
Differences	 between	 c.516G>T	 genotypes	 in	 plasma	














To	 examine	 the	 multiple	 contributions	 of	 genetic	
and	 demographic	 variables	 to	 EFV	 concentrations,	 mul-
tiple	 linear	 regression	 analyses	 were	 conducted	 in	 R.	











(car::Anova).	 Relative	 contributions	 (R2)	 of	 significant	




















Kruskal-	Wallis	 tests	 following	 random	 samplings	 from	
simulated	 population	 (side	 effect	 group)	 distributions	
of	plasma	concentrations.	Power	to	detect	a	significant	
difference	 in	 side	 effect	 incidence	 between	 CYP2B6	
genotype	 groups	 was	 estimated	 by	 performing	 10,000	




Participant characteristics, drug 
concentrations, and genotypes





centration,	 and	 demographic	 data.	 CYP2B6	 c.516	 G>T	
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(61%)	 patients	 had	 plasma	 EFV	 concentrations	 within,	
33	 (22%)	below,	and	28	 (17%)	above	 the	proposed	 thera-
peutic	window	of	1000–	4000 ng/ml.	The	median	(range)	
of	 plasma	 8OH-	EFV	 concentration	 was	 202	 (25	 to	 935)	
ng/ml.	Median	(range)	MR	was	0.13	(0.01	to	5.0).	Full	de-	
identified	data	are	available	in	Supplementary	Table S1.
CYP2B6 c.516G>T genotype differences in 
EFV and 8OH- EFV concentrations and MR







The	 difference	 in	 plasma	 EFV	 concentrations	 between	
G/G	and	G/T	genotypes	was	also	 statistically	 significant	





significant	 difference	 between	 G/G	 and	 G/T	 genotypes.	
The	 Jonckheere-	Terpstra	 test	 confirmed	 a	 significant	
(p < 1 × 10−5)	“gene-	dose”	effect	 for	MR.	Plasma	8OH-	
EFV	 concentrations	 were	 significantly	 higher	 in	 G/T	
patients	 (293  ng/ml)	 compared	 to	 G/G	 (155  ng/ml)	 and	
T/T	 (137 ng/ml)	patients	 (both	post	hoc	p < 0.05),	with	
no	significant	difference	between	G/G	and	T/T	genotypes.	




therapeutic	 plasma	 EFV	 concentration	 range	 (Table  2).	
G/G	genotype	patients	were	the	most	likely	to	be	below	the	
therapeutic	range	(42%	vs.	12%	and	15%),	and	G/T	patients	
the	most	 likely	 (85%)	 to	be	within	 the	 therapeutic	range,	
whereas	 all	 patients	 with	 EFV	 plasma	 concentrations	
greater	 than	 4000  ng/ml	 (above	 EFV	 therapeutic	 range)	
were	T/T.
Contributions of genetic and demographic 




linear	 regression	 model	 assumptions.	 Genotype	 was	 the	
only	significant	explanatory	variable	 for	(natural	 log	[ln]-	
transformed)	 plasma	 EFV	 concentrations	 (see	 Table  3),	
explaining	 38%	 of	 variability.	 For	 (ln)	 plasma	 8OH-	EFV	
concentrations,	 genotype	 and	 (ln)	 weight	 variables	 were	
significant,	explaining	10%	and	7%	of	the	variability,	respec-
tively	(Table 4).	Genotype	was	the	most	significant	explan-
atory	 variable	 for	 (ln)	 MR	 followed	 by	 gender	 (Table  5),	
explaining	50%	and	3%	of	the	variability,	respectively.
Drug concentrations, genotype, and 
side effects
A	total	of	149	patients	were	included	in	the	analysis	of	
the	 association	 between	 drug	 concentrations	 and	 the	
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occurrence	 of	 side	 effects;	 seven	 patients	 had	 concen-
trations	below	the	lower	limit	of	quantification	for	one	
or	 both	 analytes	 and	 were	 excluded	 in	 this	 analysis	 to	
prevent	 bias	 caused	 by	 possible	 medication	 nonadher-
ence	 due	 to	 side	 effects.	 Fifty-	one	 percent	 of	 patients	
reported	one	or	more	side	effects.	Overall,	no	significant	
(p > 0.05)	association	between	side	effects	and	plasma	
8OH-	EFV	 concentrations	 or	 MR	 was	 found	 (Table  6).	
When	 comparing	 plasma	 EFV	 concentrations	 between	
groups,	 a	 significant	 (p  =  0.02)	 difference	 was	 found	
between	those	with	CNS	and	psychiatric	side	effects	and	
those	 without	 (none).	 Median	 plasma	 EFV	 concentra-
tions	were	higher	 in	 those	patients	 that	did	not	 report	




EFV therapeutic concentration range
Below 
(<1000 ng/ml)




G/G,	n	(%) 11a	(42) 15	(58) 0	(0)
G/T,	n	(%) 8	(15) 45	(85) 0	(0)










T A B L E  3 	 Predictors	of	ln-	transformed	plasma	EFV	concentrations	in	102	PNG	patients	with	HIV/AIDS
Variable
Co- efficient estimate   
(95% CI) p- value
Contributiona 
to model (R2)
Age	(years) 0.0066	(−0.0089	to	0.022) 0.4 0.004
Male	gender 0.19	(−0.16	to	0.55) 0.056 0.004










Co- efficient estimate 
(95% CI) p- value
Contributiona to 
model (R2)
Age	(years) −0.002	(−0.017	to	0.012) 0.72 0.003
Male	gender −0.26	(−0.6	to	0.071) 0.12 0.034
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The	 incidence	 of	 side	 effects	 in	 patients	 with	 G/G,	





centrations	 in	 patients	 with	 side	 effects,	 the	 study	 had	
greater	than	90%	power	(alpha = 0.05)	to	identify	median	
plasma	EFV	concentrations	50%	higher	 in	CNS-	only	or	
psychiatric-	only	 groups,	 and	 100%	 higher	 in	 CNS	 and	
psychiatric	 combined	 group,	 compared	 to	 a	 median	 of	
1500  ng/ml	 in	 the	 no	 side	 effect	 group.	 However,	 the	
study	had	only	~ 53%	power	to	detect	the	observed	side	
effect	 group	 differences	 in	 plasma	 EFV	 concentrations	
(Table  6),	 whereas	 χ2	 test	 simulations	 indicated	 40%	







has	 the	 highest	 incidence	 and	 prevalence	 of	 HIV	 infec-
tions	 in	 the	 Western	 Pacific	 Region.32	 Probably	 due	 to	
logistical	and	clinical	reasons,	the	present	study	is	the	first	
to	investigate	the	relationship	between	EFV	pharmacoge-
netics	 and	 drug	 concentrations,	 as	 well	 as	 the	 influence	
of	 patient	 demographics	 and	 the	 occurrence	 of	 adverse	
events	to	drug	concentrations,	in	a	PNG	HIV/AIDS	pop-
ulation.	 In	 the	 present	 study,	 the	 frequency	 of	 the	 516T	
variant	 allele	 was	 53%,	 being	 consistent	 with	 previous	
findings	for	PNG.30,32	The	T	allele	frequency	shows	high	
variability	between	populations,	 ranging	 from	16	 to	46%	
in	Europeans,	16	to	33%	in	East	Asians,	and	35	to	45%	in	
Sub-	Saharan	Africans.31,39
A	 statistically	 significant	 increase	 in	 EFV	 concentra-
tions	 was	 found	 in	 homozygous	 carriers	 of	 the	 CYP2B6	
c.516G>T	variant	allele,	with	median	concentrations	being	
fivefold	and	approximately	threefold	higher	than	G/G	and	
G/T,	 respectively.	 Previous	 studies	 have	 replicated	 the	
association	between	CYP2B6	c.516G>T	and	plasma	EFV	
concentrations,	 including	studies	of	patients	 from	South	
Africa,11	 Zimbabwe,40	 Ghana,39	 China,21	 Switzerland,13	
T A B L E  5 	 Predictors	of	ln-	transformed	metabolic	ratio	(plasma	8OH-	EFV/EFV)	in	102	PNG	patients	with	HIV/AIDS
Variable
Co- efficient estimate   
(95% CI) p- value
Contributiona  
to model (R2)
Age	(years) −0.008	(−0.02	to	0.005) 0.2 0.01









T A B L E  6 	 Comparison	of	plasma	EFV	and	8OH-	EFV	concentrations	and	MRs	between	those	without	(none)	and	those	with	side	effects	
in	149	PNG	patients	with	HIV/AIDS	receiving	EFV	600 mg/day
Side effects N (%)
EFV ng/ml,   
median (range)
8OH- EFV ng/ml, median   
(range)
MR, median   
(range)
None 73	(49) 2011	(95–	13,212) 199	(42–	935) 0.12	(0.01–	1.25)
CNS	only 53	(36) 1497	(508–	7874) 214	(29–	876) 0.16	(0.02–	0.84)
Psychiatric	only 8	(6) 1492	(1026–	5293) 348	(58–	837) 0.18	(0.04–	0.82)
CNS	and	Psychiatric 15	(9) 1140	(272–	12,952)a	 136	(25–	711) 0.1	(0.03–	0.4)
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Taiwan,41	and	Chile.42	In	our	study,	23	patients	had	con-
centrations	 above	 4000  ng/ml	 and	 all	 were	 homozygous	
for	the	variant	allele,	demonstrating	the	potential	clinical	
relevance	 of	 the	 effect	 size	 of	 CYP2B6	 c.516G>T	 geno-
types	in	PNG	patients	with	HIV/AIDS.
Multiple	 linear	 regression	 analyses	 were	 conducted	
to	 examine	 contributions	 of	 genetic	 and	 demographic	
variables,	 such	as	age,	gender,	 and	body	weight,	 to	EFV	
concentrations.	 Previous	 studies	 showed	 contradictory	
results	 relating	 to	 the	 contribution	 of	 age,	 gender,	 and	
body	weight	to	EFV	disposition,18-	20	and,	in	our	study,	we	
could	not	establish	a	contribution	of	patient	demograph-
ics	 to	 EFV	 disposition.	 CYP2B6	 c.516G>T	 genotype	 was	
the	only	significant	explanatory	variable	for	plasma	EFV	
concentrations,	 explaining	 38%	 of	 variability.	 The	 vari-
ability	 in	 EFV	 concentrations	 caused	 by	 genotypes	 was	




concentrations	 in	 the	 PNG	 population	 might	 further	
be	 explained	 by	 other	 SNPs	 in	 CYP2B6	 as	 well	 as	 poly-










to	 glucuronidation	 by	 UGT	 enzymes,	 which	 have	 SNPs	
associated	with	variation	in	plasma	EFV	concentrations.44	
These	 alternative	 metabolic	 pathways	 could	 potentially	
explain	why	the	patients	with	T/T	genotype	in	the	present	





hances	 its	own	metabolism	by	 inducing	 the	expression	
of	 CYP2B6	 through	 activation	 of	 the	 nuclear	 receptors	











patient’s	 genotype;	 for	 instance,	 greater	 EFV	 autoin-
duction	 in	 patients	 with	 CYP2B6*1	 allele	 compared	 to	
*6/*6.47
Contrary	 to	 expectations,	 high	 plasma	 EFV	 concen-
trations	 were	 not	 associated	 with	 a	 higher	 incidence	




toxicities	 at	 the	 beginning	 of	 treatment,	 but	 CNS	 symp-
toms	 did	 not	 persist	 beyond	 a	 few	 weeks.11,48	 Moreover,	
not	 all	 studies	 have	 confirmed	 the	 plasma	 EFV	 concen-
tration	 and	 side	 effects	 association.12-	15	 However,	 this	































insufficient	 sample	 for	 DNA	 extraction	 in	 all	 patients),	
resulting	 in	 limited	 power	 to	 detect	 significant	 associa-
tions	 between	 side	 effects	 and	 plasma	 concentrations	 or	
genotype.
Some	 of	 the	 participants	 (~5%)	 had	 comorbidities,	
including	tuberculosis.	In	consideration	of	whether	con-
comitant	 medications	 (Table  1)	 may	 interfere	 in	 data	
interpretation,	 one	 patient	 was	 receiving	 rifampicin	
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(HREZ	 combination;	 see	Table  1),	 which	 has	 previously	
been	 reported	 to	 affect	 EFV	 concentrations.41	 However,	
the	drug	concentrations	for	this	patient	did	not	differ	from	
the	 other	 patients’	 concentrations,	 and	 the	 plasma	 EFV	
concentration	was	within	the	therapeutic	range.	The	other	









In	 conclusion,	 the	 relationship	 between	 CYP2B6	
c.516G>T	 genotype,	 drug	 concentrations,	 and	 adverse	
effects,	in	PNG	HIV/AIDS	patients	was	assessed	for	the	first	
time.	 CYP2B6	 c.516G>T	 genotypes	 are	 a	 strong	 predictor	
of	 plasma	 EFV	 concentrations	 and	 MR,	 with	 the	 516T/T	
genotype	strongly	associated	with	higher	plasma	efavirenz	
concentrations	and	lower	MR.	However,	CYP2B6	c.516T/T	
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